Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas

Nermin Kady, Suhaib Abdelrahman, Ahmar Rauf, Alyssa Burgess, Jonathan Weiss, Hirushi Gunasekara, Neal Thomas Ramseier, Ira P Maine, Alejandro Zevallos-Morales, Vanessa Perez-Silos, Ashley Wolfe, Alexandra Hristov, Noah A Brown, Kedar V Inamdar, Maria Sverdlov, Ying Samuel Hu, Carlos Murga-Zamalloa, Chenguang Wang, Ryan A Wilcox

Blood blood.2024025484.

https://doi.org/10.1182/blood.2024025484

Published: 2024

Includes: Multimedia, Supplemental data

Journal Articles

Outcomes of Sequenced Therapy in Mantle Cell Lymphoma in Patients Treated with First-Line Autologous Stem Cell Transplantation and Second-Line BTK Inhibitor

Michael McLane, Victoria Nachar, Shannon A. Carty, Mark S Kaminski, Tycel J. Phillips, Dahlia Sano, Jonathan Weiss, Ryan A. Wilcox, Iman Ahmed, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 6348.

https://doi.org/10.1182/blood-2024-209170

Published: 2024

Journal Articles

Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

Iman Ahmed, Victoria Nachar, Lydia Benitez, Shannon A. Carty, Dahlia Sano, Ryan A. Wilcox, XI Yang, Jonathan Weiss, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 3105.

https://doi.org/10.1182/blood-2024-205406

Published: 2024

Journal Articles

Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study

XI Yang, Iman Ahmed, Victoria Nachar, Shannon A. Carty, Ryan A. Wilcox, Jonathan Weiss, Dahlia Sano, Tycel J. Phillips, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 4477.

https://doi.org/10.1182/blood-2024-211076

Published: 2024

Journal Articles

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Blood (2024) 144 (3): 272–282.

https://doi.org/10.1182/blood.2023022730

Published: 2024

Includes: Supplemental data

Journal Articles

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Blood (2024) 143 (16): 1565–1575.

https://doi.org/10.1182/blood.2023022432

Published: 2024

Journal Articles

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Blood (2024) 143 (6): 522–534.

https://doi.org/10.1182/blood.2023022020

Published: 2024

Includes: Supplemental data

Journal Articles

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

Blood (2023) 142 (Supplement 1): 203.

https://doi.org/10.1182/blood-2023-173708

Published: 2023

Journal Articles

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Blood (2023) 142 (Supplement 1): 1897.

https://doi.org/10.1182/blood-2023-173707

Published: 2023

Journal Articles

Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma

Manisha Lin, Jonathan Weiss, Tycel J. Phillips, Dahlia Sano, Shannon A. Carty, Monalisa Ghosh, Iman Ahmed, Victoria Nachar, David Hutton, Yasmin H. Karimi

Blood (2023) 142 (Supplement 1): 256.

https://doi.org/10.1182/blood-2023-182244

Published: 2023

Journal Articles

Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing

Jan-Michel Heger, Julia Mattlener, Philipp Gödel, Hyatt Balke-Want, Noëlle Sieg, Nadine Kutsch, Kerstin Becker, Jonathan Weiss, H. Christian Reinhardt, Michael Hallek, Peter Borchmann, Bastian von Tresckow, Sven Borchmann

Blood (2022) 140 (Supplement 1): 3537–3538.

https://doi.org/10.1182/blood-2022-162420

Published: 2022

Journal Articles

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

Blood (2021) 137 (16): 2267–2271.

https://doi.org/10.1182/blood.2020008609

Published: 2021

Includes: Supplemental data

Journal Articles

Mechanisms of Venetoclax Resistance in Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 263.

https://doi.org/10.1182/blood.V130.Suppl_1.263.263

Published: 2017

Journal Articles

A Selective and Potent Rock 2 Inhibitor (KD025) Decreases Human STAT3-Dependent IL-21 and IL-17 Production and Experimental Chronic Graft-Versus-Host Disease (cGVHD)

Alexandra Zanin-Zhorov, PhD, Ryan Flynn, Leo Luznik, MD, Angela Panoskaltsis-Mortari, PhD, Du Jing, Katelyn Goodman, Jonathan Weiss, PhD, Melanie Nyuydzefe, Wei Chen, PhD, Jonathan S Serody, MD, Kelli PA MacDonald, Geoffrey R Hill, John O'Shea, MD, Maria Roche, Sara Weiss, PhD, Samuel Waksal, PhD, Bruce R. Blazar, MD

Blood (2014) 124 (21): 540.

https://doi.org/10.1182/blood.V124.21.540.540

Published: 2014

Journal Articles

In Vivo Development of Murine NK Cells Early after Congeneic BMT: Effects of MHC Molecules, and the Administration of hIL-15.

Isabel Barao-Silvestre, PhD, Doug Redelman, PhD, Erik Ames, Jonathan Weiss, PhD, Kai Sun, PhD, Lisbeth Welniak, PhD, John Ortaldo, PhD, Robert Wiltrout, PhD, William Murphy, PhD

Blood (2008) 112 (11): 2334.

https://doi.org/10.1182/blood.V112.11.2334.2334

Published: 2008

NARROW

The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas

Outcomes of Sequenced Therapy in Mantle Cell Lymphoma in Patients Treated with First-Line Autologous Stem Cell Transplantation and Second-Line BTK Inhibitor

Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study

Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial

MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study

Cost Effectiveness of Mosunetuzumab and CAR-T Cell Therapy in Relapsed/Refractory Follicular Lymphoma

Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

Mechanisms of Venetoclax Resistance in Chronic Lymphocytic Leukemia

A Selective and Potent Rock 2 Inhibitor (KD025) Decreases Human STAT3-Dependent IL-21 and IL-17 Production and Experimental Chronic Graft-Versus-Host Disease (cGVHD)

In Vivo Development of Murine NK Cells Early after Congeneic BMT: Effects of MHC Molecules, and the Administration of hIL-15.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only